Skip to main navigation Skip to search Skip to main content

Recent advances in the therapeutic potential of emodin for human health

  • Javad Sharifi-Rad
  • , Jesús Herrera-Bravo
  • , Senem Kamiloglu
  • , Katia Petroni
  • , Abhay Prakash Mishra
  • , Margalida Monserrat-Mesquida
  • , Antoni Sureda
  • , Miquel Martorell
  • , Dossymbetova Symbat Aidarbekovna
  • , Zura Yessimsiitova
  • , Alibek Ydyrys
  • , Christophe Hano
  • , Daniela Calina
  • , William C. Cho
  • Universidad Santo Tomás, Santiago
  • Universidad de la Frontera
  • Uludag University
  • University of Milan
  • Hemwati Nandan Bahuguna Garhwal University
  • Fundació Institut d'Investigació Sanitària Illes Balears
  • Instituto de Salud Carlos III (ISCIII)
  • Universidad de Concepción
  • Kazakh Russian Medical University
  • Al Farabi Kazakh National University
  • Université d'Orléans
  • Craiova University of Medicine and Pharmacy
  • Queen Elizabeth Hospital Hong Kong

Research output: Contribution to journal › Review article › peer-review

105 Scopus citations

Abstract

Emodin (1,3,8-trihydroxy-6-methylanthraquinone) is a bioactive compound, a natural anthraquinone aglycone, present mainly in herbaceous species of the families Fabaceae, Polygonaceae and Rhamnaceae, with a physiological role in protection against abiotic stress in vegetative tissues. Emodin is mainly used in traditional Chinese medicine to treat sore throats, carbuncles, sores, blood stasis, and damp-heat jaundice. Pharmacological research in the last decade has revealed other potential therapeutic applications such as anticancer, neuroprotective, antidiabetic, antioxidant and anti-inflammatory. The present study aimed to summarize recent studies on bioavailability, preclinical pharmacological effects with evidence of molecular mechanisms, clinical trials and clinical pitfalls, respectively the therapeutic limitations of emodin. For this purpose, extensive searches were performed using the PubMed/Medline, Scopus, Google scholar, TRIP database, Springer link, Wiley and SciFinder databases as a search engines. The in vitro and in vivo studies included in this updated review highlighted the signaling pathways and molecular mechanisms of emodin. Because its bioavailability is low, there are limitations in clinical therapeutic use. In conclusion, for an increase in pharmacotherapeutic efficacy, future studies with carrier molecules to the target, thus opening up new therapeutic perspectives.

Original languageEnglish
Article number113555
JournalBiomedicine and Pharmacotherapy
Volume154
DOIs
StatePublished - Oct 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Clinical trials
  • Emodin
  • Molecular mechanisms
  • Pharmacological properties
  • Signaling pathways

Fingerprint

Dive into the research topics of 'Recent advances in the therapeutic potential of emodin for human health'. Together they form a unique fingerprint.

Cite this